Conjugated drug development platform

Serilink is a company specializes in bioconjugation for conjugated drug development. We are a spin-off from chemistry department of HKU. We are utilizing our in-house novel conjugation technology to develop various conjugated drug, with a focus on antibody-drug conjugate (ADC), peptide-drug conjugate (PDC) and radionuclide-drug conjugate (RDC). We are seeking funding to support our pre-clinical studies for our PCC and also finding collaborators for co-development project.